Oak Associates Ltd. OH Sells 150 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Oak Associates Ltd. OH trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 2.0% in the 4th quarter, Holdings Channel reports. The firm owned 7,365 shares of the biotechnology company’s stock after selling 150 shares during the quarter. Oak Associates Ltd. OH’s holdings in United Therapeutics were worth $2,599,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC raised its holdings in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock worth $1,567,253,000 after acquiring an additional 32,213 shares in the last quarter. FMR LLC lifted its holdings in shares of United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after acquiring an additional 393,777 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of United Therapeutics by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock valued at $401,184,000 after purchasing an additional 44,277 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in United Therapeutics by 28.5% in the 4th quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company’s stock worth $250,179,000 after purchasing an additional 157,363 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on UTHR shares. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $388.25.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raymond Dwek sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at $497,962.50. The trade was a 69.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 87,500 shares of company stock valued at $30,640,680 over the last quarter. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $278.89 on Friday. United Therapeutics Co. has a one year low of $230.39 and a one year high of $417.82. The company has a 50-day simple moving average of $324.67 and a two-hundred day simple moving average of $351.68. The firm has a market capitalization of $12.53 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the firm earned $4.36 earnings per share. Analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.